Program
Anti-SIRPalpha Monoclonal Antibody BYON4228
Also written as “BYON4228 + Rituximab” and “BYON4228 + Pembrolizumab”.
Its studies are mostly in Lymphoma, Non-Hodgkin, led by Byondis.
Furthest: phase 1, since Feb 8, 20232 company-led studies, 2 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Byondis | 22 open or running | phase 1since Feb 8, 2023 | Feb 8, 2023 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 8, 2023First study: phase 1 study in LymphomaFirst studyNCT05737628 · 17 enrolled · Italy, Netherlands, Spain and more
- Apr 10, 2025Phase 1 study in Solid TumorNCT06932952 · 7 enrolled · Belgium, Spain, United Kingdom
TargetBeta
SIRPA →read by rule
“A humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting human signal-regulatory protein alpha (SIRPa; CD172a), ”NCIt, by rule
Other programs on SIRPA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-SIRPa Monoclonal Antibody BI 770371rule | Boehringer Ingelheim | phase 2 | 4 |
| Anti-SIRPa Monoclonal Antibody DS-1103rule | Daiichi Sankyo | phase 2 | 2 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06932952Solid Tumor · Belgium, Spain, United Kingdom | 1 | Active, not recruiting | Apr 2026 | 7 |
| NCT05737628Lymphoma · Italy, Netherlands, Spain and more | 1 | Active, not recruiting | Feb 2026 | 17 |
How it is read
Names in the registry
- “BYON4228 + Rituximab”, 1 entry
- “BYON4228 + Pembrolizumab”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, Non-Hodgkin, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.